US Stock MarketDetailed Quotes
ITOS ITeos Therapeutics
- 10.740
- -0.040-0.37%
Close Apr 30 16:00 ET
- 10.740
- 0.0000.00%
Post 16:25 ET
386.27MMarket Cap-3409P/E (TTM)
10.880High10.690Low195.10KVolume10.790Open10.780Pre Close2.10MTurnover0.78%Turnover RatioLossP/E (Static)35.97MShares18.24052wk High0.67P/B267.51MFloat Cap8.20052wk Low--Dividend TTM24.91MShs Float52.430Historical High--Div YieldTTM1.76%Amplitude8.200Historical Low10.764Avg Price1Lot Size
ITeos Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 6.69%-103.76M | 49.34%-13.77M | -14.12%-33.89M | 2.56%-29.55M | -10.64%-26.56M | -121.67%-111.19M | 53.80%-27.17M | -104.91%-29.7M | -66.10%-30.32M | -62.29%-24M |
| Net income from continuing operations | -216.54%-112.64M | -249.37%-30.55M | -3,353.28%-32.24M | -709.67%-34.3M | -122.35%-15.55M | -54.95%96.65M | -88.94%20.45M | -98.58%991K | 121.26%5.63M | 614.13%69.58M |
| Depreciation and amortization | 11.83%898K | 1.79%227K | 9.27%224K | 15.38%225K | 23.33%222K | 33.17%803K | 47.68%223K | 16.48%205K | 30.00%195K | 42.86%180K |
| Other non cash items | ---- | ---- | ---- | ---- | 0.00%2K | -16.67%10K | 50.00%3K | 50.00%3K | 0.00%2K | -66.67%2K |
| Change In working capital | 96.15%-8.8M | 122.21%11.55M | 82.88%-6.27M | 100.24%101K | 85.52%-14.18M | -180.40%-228.49M | 79.02%-52.01M | -106.89%-36.62M | -968.50%-41.91M | -2,366.24%-97.96M |
| -Change in receivables | -172.50%-7.32M | -160.62%-2.3M | -249.25%-3.04M | -545.42%-3.74M | -77.38%1.75M | 192.72%10.1M | 164.71%3.79M | 4.82%-869K | 81.64%-579K | 908.87%7.75M |
| -Change in prepaid assets | -68.81%184K | 737.85%1.84M | 32.37%-2.36M | -81.49%472K | -87.29%230K | 105.00%590K | 94.75%-288K | 45.47%-3.48M | 718.93%2.55M | 267.14%1.81M |
| -Change in payables and accrued expense | 43.04%8.38M | 33,440.63%10.67M | 93.17%-768K | 110.50%2.91M | -109.88%-4.43M | -52.14%5.86M | -101.08%-32K | -1,281.60%-11.24M | -442.54%-27.68M | 19,131.76%44.81M |
| -Change in other working capital | 95.90%-10.04M | 102.43%1.35M | 99.47%-111K | 102.84%460K | 92.29%-11.74M | -183.16%-245.03M | 76.83%-55.48M | -103.91%-21.03M | -5,340.13%-16.19M | -3,972.94%-152.33M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 6.69%-103.76M | 49.34%-13.77M | -14.12%-33.89M | 2.56%-29.55M | -10.64%-26.56M | -121.67%-111.19M | 53.80%-27.17M | -104.91%-29.7M | -66.10%-30.32M | -62.29%-24M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 116.29%72.66M | 113.83%61.56M | 21,712.38%22.69M | 4,011.09%20.1M | -9,712.38%-31.69M | -35,814.81%-446.06M | -276,372.05%-445.12M | 80.26%-105K | -12.23%-514K | -254.95%-323K |
| Net PPE purchase and sale | -216.20%-2.97M | -1,093.16%-1.4M | -804.82%-751K | -36.99%-700K | 47.58%-119K | 20.58%-938K | 27.78%-117K | 84.34%-83K | -27.43%-511K | -157.95%-227K |
| Net investment purchase and sale | 117.02%75.72M | 114.15%62.97M | --23.53M | --20.8M | ---31.58M | ---445M | ---445M | --0 | --0 | --0 |
| Net other investing changes | 17.50%-99K | -1,700.00%-16K | ---- | ---- | ---- | -96.72%-120K | 0.00%1K | -1,000.00%-22K | 94.74%-3K | -3,100.00%-96K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 116.29%72.66M | 113.83%61.56M | 21,712.38%22.69M | 4,011.09%20.1M | -9,712.38%-31.69M | -35,814.81%-446.06M | -276,372.05%-445.12M | 80.26%-105K | -12.23%-514K | -254.95%-323K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -43.90%1.11M | -77.66%307K | 1,100.00%10K | -21.58%218K | 73.57%578K | -45.78%1.98M | -41.68%1.37M | -100.23%-1K | 42.56%278K | -50.07%333K |
| Proceeds from stock option exercised by employees | 20.32%1.11M | -2.54%307K | 1,100.00%10K | -21.58%218K | 73.57%578K | -68.57%925K | -80.79%315K | -100.23%-1K | 42.56%278K | -50.07%333K |
| Net other financing activities | ---- | ---- | ---- | ---- | ---- | 47.91%1.06M | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -43.90%1.11M | -77.66%307K | 1,100.00%10K | -21.58%218K | 73.57%578K | -45.78%1.98M | -41.68%1.37M | -100.23%-1K | 42.56%278K | -50.07%333K |
| Net cash flow | ||||||||||
| Beginning cash position | -66.42%285.04M | -72.84%204.4M | -72.67%216.48M | -72.63%225.6M | -66.42%285.04M | 152.29%848.84M | -16.38%752.47M | 161.37%792.15M | 156.37%824.28M | 152.29%848.84M |
| Current changes in cash | 94.60%-29.99M | 110.21%48.1M | 62.46%-11.19M | 69.81%-9.23M | -140.38%-57.67M | -207.70%-555.27M | -731.70%-470.92M | -104.93%-29.8M | -65.02%-30.56M | -68.79%-23.99M |
| Effect of exchange rate changes | 57.75%-3.6M | -130.05%-1.05M | 90.94%-895K | 107.13%112K | -214.56%-1.77M | -168.45%-8.53M | -37.18%3.49M | -22.31%-9.88M | -2,444.78%-1.57M | 21.48%-563K |
| End cash Position | -11.78%251.45M | -11.78%251.45M | -72.84%204.4M | -72.67%216.48M | -72.63%225.6M | -66.42%285.04M | -66.42%285.04M | -16.38%752.47M | 161.37%792.15M | 156.37%824.28M |
| Free cash flow | 4.82%-106.72M | 44.44%-15.16M | -16.33%-34.64M | 1.90%-30.25M | -10.09%-26.67M | -121.90%-112.13M | 53.73%-27.29M | -104.93%-29.78M | -65.27%-30.83M | -62.85%-24.23M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg